Alice S. Mims

Alice S. Mims's research focuses on blood cancers, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), with an emphasis on clinical trials testing new drugs (such as menin inhibitors, IDH inhibitors, and antibody-drug conjugates) and treatment strategies for newly diagnosed and relapsed/refractory patients. Much of this work involves multicenter clinical studies examining how specific genetic mutations (like NPM1, KMT2A, and IDH1) affect patient outcomes and response to targeted therapies, including in combination with stem cell transplantation.

Publication output has grown substantially over the last decade, rising from single digits in 2017 to a sustained high output of 50-90+ papers per year since 2023.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026